Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors

2016 ◽  
Vol 106 (3) ◽  
pp. 165-173 ◽  
Author(s):  
Seung-Yul Lee ◽  
Myeong-Ki Hong ◽  
Dong-Ho Shin ◽  
Jung-Sun Kim ◽  
Byeong-Keuk Kim ◽  
...  
2021 ◽  
Vol 8 ◽  
Author(s):  
Xi-Ying Liang ◽  
Yan Li ◽  
Xuan Qiao ◽  
Wen-Jiao Zhang ◽  
Zhi-Lu Wang

Background: Patients with diabetes represent 20–30% of the population considered for percutaneous coronary intervention (PCI) and associate with more deleterious clinical outcome, which requires the optimal strategy of dual antiplatelet therapy (DAPT). The meta-analysis aims to compare clinical outcomes between very short (1–3 months) and standard (12 months) DAPT after implanting the second-generation drug-eluting stents in patients with or without diabetes following PCI.Methods and Analysis: PubMed, Embase, Web of Science, Ovid, Cochrane Library, and ClinicalTrials.gov were searched for studies comparing the very short term and standard DAPT in patients with or without diabetes following PCI. Risk ratio with 95% confidence intervals was used to evaluate the pooled effect of discontinuous variables, and the pooled analyses were performed with RevMan 5.3 and Stata SE 14.0 software.Results: A total of 38,864 patients were randomized to the very short term DAPT (N = 19,423) vs. standard DAPT (N = 19,441). Among them, 11,476 patients were diabetes and 27,388 patients were non-diabetes. The primary outcome of the net adverse clinical event (NACE) was significantly lower in diabetic patients with very short term DAPT (risk ratio 0.72, 95% CI 0.60–0.88, p = 0.0009). The same result was also found in the major cardiac or cerebrovascular events (MACCEs) (0.87, 0.78–0.98, p = 0.03). The risk of major or minor bleeding was significantly reduced in very short term DAPT regardless of the diabetes statue (0.69, 0.52–0.93, p = 0.01 in the diabetic group, and 0.50, 0.39–0.63, p <0.0001 in the non-diabetic group). There was no statistical difference in the incidence of major bleeding, all-cause death, cardiac death, myocardial infarction, definite or probable stent thrombosis, and stroke between the very short term DAPT (1–3 months) and standard DAPT (12 months) in patients with or without diabetes.Conclusion: The very short term DAPT can significantly reduce the risk of the NACE and MACCE in patients with diabetes compared to standard DAPT. Meanwhile, the very short term DAPT can also reduce the incidence of major and minor bleeding without increasing the risk of ischemia in patients with or without diabetes (Registered by PROSPERO, CRD42020192133).Systematic Review Registration:https://www.crd.york.ac.uk/prospero/, Identifier: CRD42020192133.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2354-2354
Author(s):  
Patrick F. Fogarty ◽  
William H. Matthai ◽  
Anne Boccuti ◽  
Rolando Vega ◽  
Elaine Y Chiang ◽  
...  

Abstract Introduction Information is limited regarding in-hospital management of ACS, which typically requires invasive procedures and/or exposure to antithrombotic agents, when complicated by the most common inherited bleeding disorder, VWD. We sought to identify clinical characteristics and in-hospital outcomes among ACS patients with VWD, compared to noncoagulopathic ACS controls. Methods The study included discharges from the Nationwide Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (2004-2010). Case discharges had ICD-9 codes for both VWD and ACS; discharges with ICD-9 codes indicating an alternative bleeding disorder were excluded. Control discharges had ICD-9 codes for ACS and were matched to case discharges using state, year of discharge and hospital type (urban teaching, urban non-teaching, and rural). IDC-9 codes were used to identify presence of cardiovascular risk factors; use of coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), bare-metal stent (BMS) and/or drug-eluting stent (DES); bleeding or bruising; and transfusions of packed red blood cells (pRBCs). Unadjusted and adjusted odds ratios were obtained from conditional univariate and multivariate logistic regression analyses. Results 264 cases and 706,124 matched controls were identified. The median age was 61.5y (28-95y) and 67.0y (18-112y), respectively. 59.5% of cases were female, compared to 39.4% of controls (p<0.001). Obesity, diabetes, and hyperlipidemia occurred at a similar rates in the two groups, whereas HCV and HIV infection were more common among cases than in controls (1.1% versus 0.3% and 0.8% versus 0.1%, respectively; p=0.014 and p=0.003). Compared to controls, a significantly higher proportion of cases did not undergo PCI or CABG and were managed medically (56.9% and 48.4%, respectively; p=0.006)(Table). Cases were less likely to undergo PCI (31.4%) than controls (40.5%) (p=0.03), whereas a similar proportion of both groups underwent CABG (11.7% and 11.1%, respectively)(Table). At least one intracoronary stent was deployed in almost all cases and controls undergoing PCI (Table), but use of only BMS, which does not require as long a period of post-insertion dual antiplatelet therapy as DES, was twice as common among cases than controls (46.2% v. 22.0%, respectively; p<0.001). Reported bleeding among PCI or CABG was higher in cases compared to controls (7.2% vs 3.3% and 12.9% vs 4.0%, respectively; p=0.0472 and p=0.045). However, the use of pRBC transfusion associated with PCI or CABG was comparable (Table). The death rate was similar in both groups (4.2% and 3.6%) (Table). There were no in-hospital deaths involving cases undergoing PCI or CABG. Conclusions Among discharges associated with ACS complicated by VWD, the majority are female. Median age at hospital presentation of ACS is lower and rates of cardiovascular risk factors appear to be comparable to the noncoagulopathic ACS population. PCI and DES are less frequently offered to patients with ACS complicated by VWD, possibly in consideration of the underlying bleeding disorder and the desire to avoid exposure to extended-duration dual antiplatelet therapy. Similar rates of pRBC transfusion in the setting of PCI or CABG, however, suggest no increase in clinically important in-hospital bleeding due to VWD. These data suggest that CABG or PCI as definitive management of ACS are safe in selected patients with VWD. Further studies are needed to determine long-term outcomes and whether PCI and DES should be made more widely available to ACS patients with VWD. Disclosures: Fogarty: Bayer Healthcare: Honoraria; Baxter Healthcare: Consultancy, Research Funding; Biogen IDEC: Consultancy, Honoraria, Research Funding; CSL Behring: Research Funding; Grifols: Consultancy; NovoNordisk: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding.


2021 ◽  
Vol 77 (18) ◽  
pp. 129
Author(s):  
Manesh Kumar Gangwani ◽  
Abeer Aziz ◽  
Shazib Sagheer ◽  
Priyanka Ahuja ◽  
Wade Lee-Smith ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document